Claims for Patent: 7,632,490

Summary for Patent: 7,632,490

Title:	Use of IL-1 antagonists to treat gout
Abstract:	Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
Inventor(s):	Vicary; Catherine (New York, NY), Mellis; Scott (New Rochelle, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	12/200,681
Patent Claims:	1. A method of treating drug-induced gout flares, comprising administering to a subject being treated with a therapeutic agent for gout, a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of the gout flare is reduced by at least about 50% relative to not administering the IL-1 antagonist. 2. The method of claim 1, wherein administration of the IL-1 antagonist is subcutaneous or intravenous administration. 3. The method of claim 2, wherein administration is single or multiple subcutaneous injections or intravenous infusions 4. The method of claim 1, wherein said therapeutically effective amount of an IL-1 antagonist is between 1 to 30 mg/kg. 5. The method of claim 4, wherein a administration is a one or more subcutaneous or intravenous dose(s) of a therapeutically effective amount of IL-1 antagonist of up to about 100 to 2000 mg. 6. The method of claim 5, wherein an initial dose is between about 80-500 mg of the IL-1 antagonist administered subcutaneously, and one or more subsequent doses of 40-250 mg are administered subcutaneously. 7. The method of claim 1, wherein the IL-1 antagonist is rilonacept. 8. The method of claim 1, wherein the incidence of the drug-induced gout flare is reduced by at least about 60% relative to not administering the IL-1 antagonist. 9. The method of claim 8, wherein the incidence of the drug-induced gout flare is reduced by at least about 75% relative to not administering the IL-1 antagonist. 10. The method of claim 9, wherein the incidence of the drug-induced gout flare is reduced by at least about 80% relative to not administering the IL-1 antagonist. 11. The method of claim 6, wherein frequency of administration of said subsequent doses is weekly, biweekly or monthly. 12. The method of claim 1, wherein said therapeutic agent for gout is a xanthine oxidase inhibitor. 13. The method of claim 12, wherein said xanthine oxidase inhibitor is allopurinol or febuxostat. 14. The method of claim 1, wherein said therapeutic agent for gout is a urate oxidase. 15. The method of claim 14, wherein said urate oxidase is uricase, rasburicase or pegylated uricase. 16. The method of claim 1, wherein said therapeutic agent for gout is a uricosuric agent. 17. The method of claim 16, wherein said uricosuric agent is probenecid, sulfinpyrazone, benzbromarone or fenofibrate.

Details for Patent 7,632,490

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	07/12/2002		2039-02-26
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	01/06/2006		2039-02-26
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	02/27/2008		2039-02-26